Rifaximin Is Effective for the Treatment of Clostridium difficile—Associated Diarrhea: Results of an Open-Label Pilot Study

Table 1

Patient demographics and characteristics.

Patient	Age	Sex	Reason for hospitalization	Comorbidities	Previous CDAD
(1)	68	F	Deep vein thrombosis	Hypertension, CRI, nonsmall cell lung cancer, aortic valve repair, Hodgkin’s lymphoma	No
(2)	62	F	Neutropenic fever and reinduction of chemotherapy	Acute myelogenous leukemia, hypertension, uterine cancer, history of VRE	Yes
(3)	68	F	Acute renal failure, volume depletion	Breast cancer, COPD, CHF, MGUS, Klebsiella pneumonia infection, anemia	No
(4)	41	M	CHF exacerbation (ejection fraction 15%)	Congenital cardiomyopathy; CRI	No
(5)	76	F	Pneumonia	hypertension, diabetes mellitus, ESRD	No
(6)	46	M	Diverticulitis requiring partial colectomy	Hypertension, umbilical hernia	No
(7)	39	M	Diarrhea, volume depletion	Right inguinal hernia	No
(8)	39	M	Failure to thrive	Extramedullary CML, graft-versus-host disease, pleural effusions, depression	No

CDAD: Clostridium difficile-associated diarrhea; CHF: chronic heart failure; CML: chronic myeloid leukemia; COPD: chronic obstructive pulmonary disease; CRI: chronic renal insufficiency; ESRD: end-stage renal disease; MGUS: monoclonal gammopathy of unknown significance; VRE: vancomycin-resistant Enterococcus.